Blueprint Medicines Corp (BPMC)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$93.87
Buy
$94.25
$0.68 (+0.73%)
Prices updated at 16 Dec 2024, 15:28 EST
| Prices minimum 15 mins delay
Prices in USD
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2022 | 2023 |
|---|---|---|
| 204m | 249m | |
| 186m | 241m | |
| -529m | -482m | |
| -259.06 | -193.29 | |
| -558m | -507m | |
| -517m | -470m | |
| Sales, General and administrative | 237m | 295m |
| Interest expenses | - | - |
| Provision for income taxes | 5m | 968,000 |
| Operating expenses | 715m | 723m |
| Income before taxes | -552m | -506m |
| Net income available to common shareholders | -558m | -507m |
| -9.35 | -8.37 | |
| Net interest income | -17m | -19m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -9.35 | -8.37 |
| Free cash flow per share | -11.1382 | -8.162 |
| Book value/share | 10.6791 | 3.3135 |
| Debt equity ratio | 0.417779 | 2.222557 |
Balance sheet
Year | 2022 | 2023 |
|---|---|---|
| Current assets | 1,047m | 808m |
| Current liabilities | 183m | 215m |
| Total capital | 637m | 339m |
| Total debt | 242m | 332m |
| Total equity | 515m | 131m |
| Total non current liabilities | - | - |
| Loans | 122m | 209m |
| Total assets | 1,350m | 1,049m |
| Total liabilities | - | - |
| Cash and cash equivalents | 120m | 71m |
| Common stock | 60m | 61m |
Cash flow
Year | 2022 | 2023 |
|---|---|---|
| Cash at beginning of period | 215m | 125m |
| Cash dividends paid | - | - |
| -511m | -453m | |
| Investments (gains) losses | -150m | 274m |
| 125m | 82m | |
| Net income | - | - |
| -502m | -437m | |
| -9m | -16m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
